Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.